Real-world multicenter comparison of effectiveness between tofacitinib and vedolizumab in patients with Ulcerative Colitis after failure to at least one anti-TNF agent

被引：0
|
作者：
Buisson, A. [1 ]
Nachury, M. [2 ]
Fumery, M. [3 ]
Guilmoteau, T. [1 ]
Leclerc, E. [1 ]
Altwegg, R. [4 ]
Serrero, M. [5 ]
Mathieu, N. [6 ]
Treton, X. [7 ]
Vuitton, L. [8 ]
Pereira, B. [9 ]
Amiot, A. [10 ]
Bouguen, G. [11 ]
机构：
[1] Univ Hosp Estaing, Dept Gastroenterol, IBD Unit, Clermont Ferrand, France
[2] CHRU Lille, IBD Unit, Lille, France
[3] CHU Amiens, IBD Unit, Amiens, France
[4] CHU Montpellier, IBD Unit, Montpellier, France
[5] AP HM, IBD Unit, Marseille, France
[6] CHU Grenoble, IBD Unit, Grenoble, France
[7] AP HP Beaujon Hosp, IBD Unit, Paris, France
[8] CHU Besancon, IBD Unit, Besancon, France
[9] Univ Hosp Estaing, DRCI Biostat Unit, Clermont Ferrand, France
[10] AP HP Creteil Hosp, IBD Unit, Paris, France
[11] CHU Rennes, IBD Unit, Rennes, France
来源：
JOURNAL OF CROHNS & COLITIS | 2022年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
DOP76
引用
收藏
页码：I120 / I120
页数：1
相关论文
共 50 条
  • [31] One-Year Comparison of Clinical and Endoscopic Outcomes of Tofacitinib Versus Vedolizumab for Ulcerative Colitis After Anti-Tumor Necrosis Factor Failure: A Real-World Cohort Study in the United States
    Dalal, R.
    Sharma, P.
    Bains, K.
    Pruce, J.
    Allegretti, J.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 677 - 678
  • [32] Tofacitinib versus Vedolizumab Among Bio-naive Patients With Ulcerative Colitis: A Real-World Propensity-Weighted Comparison
    Gros, B.
    Constantine-Cooke, N.
    Kennedy, J.
    Elford, A. T.
    O'Hare, C.
    Noble, C.
    Jones, G. R.
    Arnott, I. D.
    Plevris, N.
    Lees, C. W.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I102 - I103
  • [33] ONE-YEAR COMPARISON OF CLINICAL AND ENDOSCOPIC OUTCOMES OF TOFACITINIB VERSUS VEDOLIZUMAB FOR ULCERATIVE COLITIS AFTER ANTI-TUMOR NECROSIS FACTOR FAILURE: A REAL-WORLD COHORT STUDY IN THE UNITED STATES
    Dalal, Rahul S.
    Sharma, Puza P.
    Bains, Kanwal
    Pruce, Jordan C.
    Allegretti, Jessica R.
    GASTROENTEROLOGY, 2023, 164 (06) : S651 - S651
  • [34] Compared efficacy and safety of vedolizumab and infliximab in ulcerative colitis after failure of a first subcutaneous anti-TNF agent: a multicentre cohort study
    Hupe, Marianne
    Riviere, Pauline
    Nancey, Stephane
    Roblin, Xavier
    Altwegg, Romain
    Filippi, Jerome
    Fumery, Mathurin
    Bouguen, Guillaume
    Peyrin-Biroulet, Laurent
    Bourreille, Arnaud
    Caillo, Ludovic
    Simon, Mireille
    Goutorbe, Felix
    Laharie, David
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2020, 51 (09) : 852 - 860
  • [35] Effectiveness of a second-line anti-TNFα agent compared to a different mechanism of action after first anti-TNFα failure in ulcerative colitis: CambiaCU Study
    Lopez-Vico, M.
    Hernandez-Martinez, A.
    Soto-Escribano, P.
    Rojas-Feria, M.
    Cornejo-Jimenez, A.
    Caballero-Mateos, A. M.
    Trapero-Martinez, A. M.
    Sanchez-Capilla, A. D.
    Cabello-Tapia, M. J.
    Martin-Rodriguez, M. D. M.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1293 - I1293
  • [36] Real-world clinical and endoscopic outcomes after one year tofacitinib treatment in ulcerative colitis
    Straatmijer, Tessa
    van Gennep, Sara
    Duijvestein, Marjolijn
    Ponsioen, Cyriel I. J.
    Gecse, Krisztina B.
    D'Haens, Geert R.
    Lowenberg, Mark
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2021, 33 (10) : 1288 - 1297
  • [37] Comparing Patient-Reported Outcomes Among Anti-TNF Experienced Patients With Ulcerative Colitis Initiating Vedolizumab Versus Tofacitinib
    Kappelman, Michael D.
    Long, Millie D.
    Zhang, Xian
    Lin, Feng-Chang
    Weisbein, Laura
    Chen, Wenli
    Burris, Jessica
    Dorand, Jennifer E.
    Parlett, Lauren E.
    Fehlmann, Tara
    Brensinger, Colleen M.
    Haynes, Kevin
    Nair, Vinit
    Kaul, Alan F.
    Dobes, Angela
    Lewis, James D.
    CROHNS & COLITIS 360, 2023, 5 (03)
  • [38] Effectiveness of tofacitinib in a real-world Israeli cohort of patients with moderate-severe ulcerative colitis
    Biron, I. Avni
    Shitrit, A. Bar-Gil
    Koslowsky, B.
    Kopylov, U.
    Levartovsky, A.
    Weisshof, R.
    Aviv-Cohen, N.
    Maharshak, N.
    Hovel, D.
    Naftali, T.
    Goren, I.
    Snir, I.
    Ollech, J.
    Banai, H.
    Lena, B.
    Dotan, I.
    Yanai, H.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S498 - S499
  • [39] Real-world evidence comparison of the effectiveness of ustekinumab with anti-TNF or vedolizumab in ulcerative colitis: 1-year maintenance therapy results from the prospective, observational RUN-UC study
    Bokemeyer, B.
    Plachta-Danielzik, S.
    Howaldt, S.
    Mohl, W.
    Efken, P.
    Ehehalt, R.
    Kahl, M.
    Krause, T.
    Trentmann, L.
    Luegering, A.
    Schnoy, E.
    Jochum, C.
    Salmon, S. Fajardo
    Hartmann, P.
    Gilman, E.
    Schreiber, S.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1470 - I1471
  • [40] Effect of Tofacitinib on One-Year Colectomy Risk in Anti-TNF Refractory Ulcerative Colitis: A Prospective Multicenter Italian Study
    Gabrielli, Anna Maria Carvalhas
    Ferretti, Francesca
    Monico, Camilla Maria
    Tombetti, Enrico
    Maconi, Giovanni
    Romeo, Samanta
    Sed, Nicole Piazza O.
    Caprioli, Flavio
    Mazzola, Anna Maria
    Alicante, Saverio
    Berte, Roberto
    Lolli, Elisabetta
    Scribano, Maria Lia
    Buscarini, Elisabetta
    Ricci, Chiara
    Carmagnola, Stefania
    Ardizzone, Sandro
    Cannatelli, Rosanna
    DIGESTIVE DISEASES AND SCIENCES, 2024, 69 (05) : 1785 - 1792
12345